SABS

Sab Biotherapeutics Stock Analysis

AI Rating

Good
  • Quality0/10
  • Growth↑ 8/10
  • Value↑ 9/10
Sab Biotherapeutics sales and earnings growth
SABS Growth
Good
  • Revenue Y/Y↓ -100.00%
  • EPS Y/Y↑ 105.98%
  • FCF Y/Y↓ -31.99%
Sab Biotherapeutics gross and profit margin trends
SABS Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ -93.47%
Sab Biotherapeutics net debt vs free cash flow
SABS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 56.2

Sab Biotherapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗